Stockhead TV
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
Health & Biotech
AdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapy
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 1
News
ASX Small Caps and IPO Weekly Wrap: Gold and medicine are the best medicine
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Cettire rejects AFR claims, GDP’s gone back to the 90’s and ASX200 ends above the ice
Health & Biotech
AdAlta’s Ad-214 extension study reaches milestone for Phase II clinical studies and partnering
News
ASX Small Caps Lunch Wrap: GDP drama is over, now markets brace for the lack of drama, drama
Health & Biotech
ASX Health Stocks: Atomo pops 90pc after purchase order; AdAlta up 20pc on Phase 1 results
News
Top 10 at 11: Dicker Data founder sells $90.47 million worth of stock following divorce settlement
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Countdown on to AdAlta trial results as biotech advances partner discussions
Health & Biotech
AdAlta advancing partnering programs as AD-214 participants receive final dose
Stockhead TV
What’s in store for 2024: AdAlta
Experts
Money Talks: Keep an eye on these tasty precious metal and biotech plays in 2024
Stockhead TV
Long Shortz with AdAlta: How the company has potentially broken the malaria life cycle
News